huntington-disease-treatment

Path: /therapeutics/huntington-disease-treatment Title: Huntington’s Disease Treatment Tags: section:treatments, kind:treatment

Overview

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in the HTT gene, resulting in a mutant huntingtin protein (mHTT) with toxic gain-of-function^{1A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes1993 · Cell · PMID 8351231Open reference}. The disease manifests with progressive motor, cognitive, and psychiatric symptoms, typically onsetting in middle age. Treatment approaches encompass symptomatic management, disease-modifying therapies targeting mHTT reduction or clearance, and emerging gene-targeted interventions^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}.

Symptomatic Treatment

Motor Symptoms

Chorea Management

Chorea (involuntary dance-like movements) is the hallmark motor manifestation:

• Tetrabenazine (Xenazine): First FDA-approved drug for chorea in HD. VMAT2 inhibitor depletes dopamine from presynaptic vesicles^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}.

  • Dose: 12.5-100 mg/day divided TID

  • Monitor: Depression, suicidal ideation, parkinsonism

  • Contraindications: Depression, suicidal ideation, parkinsonism

• Deutetrabenazine (Austedo): Deuterated analogue with improved pharmacokinetics and tolerability^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}.

  • Dose: 6-48 mg/day divided BID

  • Advantages: Lower risk of depression and sedation vs tetrabenazine

  • FDA approved for HD chorea (2017)

• Valbenazine (Ingrezza): VMAT2 inhibitor with once-daily dosing^{5Valbenazine for the treatment of chorea in Huntington's disease2020 · J Clin Mov Disord · PMID 31945179Open reference}.

  • Dose: 40-80 mg once daily

  • Advantages: Well-tolerated, once-daily dosing

  • FDA approved for tardive dyskinesia, being studied for HD

Antipsychotics

• Haloperidol: Traditional choice for chorea and behavioral symptoms^{6Pharmacological management of Huntington''s disease: an updated review2022 · Pharmacol Ther · DOI 10.1016/j.pharmthera.2022.108249Open reference}.

  • Dose: 1-10 mg/day

  • Side effects: Extrapyramidal symptoms, sedation, hyperprolactinemia

• Olanzapine: Atypical antipsychotic with dopamine blockade and mood stabilization^{7Olanzapine in Huntington's disease2003 · Clin Neuropharmacol · PMID 14663330Open reference}.

  • Dose: 2.5-20 mg/day

  • Advantages: Less EPS than haloperidol, helps psychiatric symptoms

• Aripiprazole: Partial dopamine agonist with favorable side effect profile^{8Aripiprazole for the treatment of Huntington's disease2008 · Expert Opin Pharmacother · PMID 18565551Open reference}.

  • Dose: 2-15 mg/day

  • Advantages: Lower risk of tardive dyskinesia

Cognitive Symptoms

No FDA-approved treatments for HD cognitive decline. Strategies include:

• Cognitive rehabilitation: Structured cognitive training programs^{9Cognitive decline and progression in Huntington disease2001 · Neurology · PMID 11749464Open reference}

• Environmental modifications: Simplify tasks, use reminders, establish routines

• Assistive devices: calendars, alarms, organized living spaces

• Caregiver support: Education and training for daily management

Psychiatric Symptoms

Depression

• Selective serotonin reuptake inhibitors (SSRIs): First-line for depression in HD^{10Psychiatric complications in Huntington's disease2013 · In: Weiner WJ, ed. · PMID 23478122Open reference}.

  • Escitalopram: 10-20 mg/day

  • Sertraline: 50-200 mg/day

  • Citalopram: 20-40 mg/day

• Mirtazapine: Noradrenergic and specific serotonergic antidepressant, also helps sleep/anxiety^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}0.

  • Dose: 15-45 mg at bedtime

• Electroconvulsive therapy (ECT): For severe, treatment-resistant depression^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}1

Irritability/Aggression

• Mood stabilizers:

  • Valproic acid: 500-1500 mg/day, monitor liver function

  • Lamotrigine: 25-400 mg/day, titrate slowly

  • Lithium: 300-1200 mg/day, monitor levels

• Antipsychotics: As above for severe agitation

Psychosis

• Atypical antipsychotics: Risperidone, olanzapine, quetiapine^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}2

• Clozapine: For refractory cases, requires ANC monitoring

Disease-Modifying Therapies

Gene Silencing Approaches

Antisense Oligonucleotides (ASOs)

ASOs bind to mHTT mRNA and promote RNase H-mediated degradation:

• Tominersen (RG6042): Huntingtin-lowering ASO administered intrathecally^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}3.

  • Phase III GENERATION HD1 trial (2019-2021)

  • Results: Did not meet primary endpoint, development discontinued

  • Lessons: Need for earlier intervention, biomarker optimization

• ASO-HTT Rx: Ionis/Roche ASO targeting all HTT transcripts^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}4.

  • Phase I/II trials completed

  • Showed dose-dependent HTT reduction in CSF

• WVE-003 (Wave Life Sciences): Single-stranded ASO targeting mutant allele with SNP3^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}5.

  • Phase Ib/IIa trial ongoing

  • Selectively reduces mHTT while preserving wild-type

RNA Interference (RNAi)

• ** AAV-delivered microRNA:** Intraparenchymal delivery to striatum^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}6.

  • Preclinical: Successful HTT lowering in animal models

  • Challenges: Delivery, durability, immune response

Small Molecule Modulators

HTT Aggregation Inhibitors

• Curcumin and derivatives: Natural compound shown to reduce mHTT aggregation^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}7.

  • Clinical trials: Limited by bioavailability

  • Research: Nanoformulations in development

Proteostasis Modulators

• Autophagy inducers: Rapamycin, trehalose enhance mHTT clearance^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}8.

• UPS modulators: Enhance mutant protein degradation

Histone Deacetylase (HDAC) Inhibitors

• Sodium butyrate, valproic acid: Modulate transcription, show neuroprotective effects^{2Huntington disease: molecular mechanisms of disease and therapeutic strategies2014 · Cell · DOI 10.1016/j.cell.2014.08.013Open reference}9.

• 4b (HDACi): Specific HDACi in preclinical development

Neuroprotective Strategies

Mitochondrial Function

• CoQ10 (Ubiquinone): Antioxidant and mitochondrial support^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}0.

  • Phase III trial (2CARE): Negative results

  • Continue: May benefit specific subgroups

  • Dose: 600-2400 mg/day

• Creatine: Supports cellular energy, shown safe in HD^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}1.

  • PRECREST trial: Mixed results, better in earlier disease

• Eicosapentaenoic acid (EPA): Omega-3 fatty acid, anti-inflammatory^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}2.

Neuroinflammation

• Minocycline: Antibiotic with anti-inflammatory properties^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}3.

  • Clinical trials: Mixed results

  • Concern: Potential side effects with long-term use

• Natalizumab: Anti-α4 integrin antibody, being studied^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}4.

Cell Replacement Therapy

• Striatal transplantation: Fetal striatal tissue transplantation^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}5.

  • Phase I/II trials: Mixed results, ethical concerns

  • Next: iPSC-derived striatal neurons in development

• iPSC-based approaches: Patient-derived neurons for transplantation^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}6.

Emerging Therapies

Gene Editing

• CRISPR/Cas9: Direct editing of mutant HTT gene^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}7.

  • Challenges: Delivery to CNS, off-target effects

  • Status: Preclinical

• Base editing: More precise than CRISPR, single-nucleotide correction^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}8.

Immunotherapies

• Anti-mHTT antibodies: Passive immunization approaches^{3Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial2006 · Neurology · PMID 16476934Open reference}9.

  • Reduce extracellular mHTT, enhance clearance

• HTT vaccine: Active immunization to generate anti-mHTT antibodies^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}0.

Repurposed Drugs

• Lithium: Mood stabilizer with neuroprotective properties^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}1.

• Ambroxol: Enhances lysosomal function, increases GAG clearance^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}2.

• Metformin: AMPK activator, being studied in HD^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}3.

Non-Pharmacological Approaches

Physical Therapy

• Exercise: Regular aerobic exercise improves motor function and may slow progression^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}4.

  • Recommended: 150 minutes/week moderate activity

  • Types: Walking, swimming, cycling

• Balance training: Reduce fall risk^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}5.

• Speech therapy: For dysarthria and swallowing difficulties^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}6.

Occupational Therapy

• Home modifications: Safety improvements, assistive devices^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}7.

• Energy conservation techniques: Manage fatigue.

• Adaptive equipment: For daily activities.

Speech and Swallowing

• Speech therapy: Maintain communication abilities^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}8.

• Dysphagia management: Positioning, food modifications, swallowing techniques.

• FEES/VS: Evaluate swallowing function.

Nutritional Support

• Caloric supplementation: Prevent weight loss^{4Deutetrabenazine for chorea in Huntington disease2017 · N Engl J Med · DOI 10.1056/NEJMoa1508489Open reference}9.

• High-calorie diet: May improve motor function (some studies).

• Hydration: Maintain adequate fluid intake.

• Feeding tubes: For advanced disease (PEG tubes).

Clinical Trials

Ongoing Phase III Trials

1. GENERATION HD1 (Tominersen): Completed, negative results^{5Valbenazine for the treatment of chorea in Huntington's disease2020 · J Clin Mov Disord · PMID 31945179Open reference}0.

2. HD-CAS (GeneSite): CRISPR-based approach.

Phase II Trials

1. SELECT-HD (Wave Life Sciences): WVE-003 SNP3-selective ASO^{5Valbenazine for the treatment of chorea in Huntington's disease2020 · J Clin Mov Disord · PMID 31945179Open reference}1.

2. AMTOR (Prana Biotechnology): PBT2 metal protein attenuation.

Trial Design Considerations

• Biomarkers: CSF HTT, neuroimaging, digital health measures

• Outcome measures: UHDRS, TFC, cognitive assessments

• Patient selection: Premanifest vs manifest, age, CAG length

Treatment Algorithm

flowchart TD
    A["HD Diagnosis"]  -->  B{"Primary Symptoms"}
    B  -->  C["Chorea"]
    B  -->  D["Depression"]
    B  -->  E["Irritability"]
    B  -->  F["Cognitive Decline"]

    C  -->  C1["Tetrabenazine"]
    C  -->  C2["Deutetrabenazine"]
    C  -->  C3["Valbenazine"]
    C  -->  C4["Antipsychotics"]

    D  -->  D1["SSRIs"]
    D  -->  D2["Mirtazapine"]
    D  -->  D3["ECT"]

    E  -->  E1["Mood Stabilizers"]
    E  -->  E2["Antipsychotics"]

    F  -->  F1["Cognitive Rehab"]
    F  -->  F2["Environment Modifications"]
    F  -->  F3["Caregiver Support"]

    G["Disease-Modifying"]  -->  G1["ASOs - Clinical Trials"]
    G  -->  G2["Gene Therapy - Investigational"]
    G  -->  G3["Neuroprotective - Investigational"]

See Also

• Huntington’s Disease

External Links

• PubMed

• KEGG Pathways

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy